Adjuvant immunotherapy for liver cancer after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 100 years old.
- You must have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- You must have had surgery or ablation to remove the tumor, and the doctor confirmed no cancer cells were left behind.
- You must have at least one high-risk feature, like a tumor larger than 5 cm, multiple tumors, or blood vessel invasion.
- You must be generally healthy, with good liver and kidney function, and not have other severe medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug called QL1706 before surgery can help lower the risk of liver cancer coming back. It is for people with early-stage liver cancer that is at higher risk of returning, and the goal is to see if this approach is safe and effective.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of treatments—chemotherapy given directly into the liver, two immunotherapy drugs, and a targeted therapy—for people with liver cancer that is too large or complex for immediate surgery. The goal is to shrink the tumor enough to make surgery possible later.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.